Immunological Exploration of Helicobacter pylori Serotype O_(2) O-Antigen by Using a Synthetic Glycan Library
作者机构:Key Laboratory of Carbohydrate Chemistry and BiotechnologyMinistry of EducationSchool of Biotechnology & School of Life Sciences and Health EngineeringJiangnan UniversityLihu Avenue 1800WuxiJiangsu214122 China Biomolecular Systems DepartmentMax Planck Institute of Colloids and InterfacesAm Mühlenberg 1Potsdam14476 Germany Wuxi School of MedicineJiangnan UniversityLihu Avenue 1800WuxiJiangsu214122 China
出 版 物:《Chinese Journal of Chemistry》 (中国化学(英文版))
年 卷 期:2024年第42卷第3期
页 面:243-251页
核心收录:
学科分类:1001[医学-基础医学(可授医学、理学学位)] 100102[医学-免疫学] 0703[理学-化学] 10[医学]
基 金:financial support from the National Natural Science Foundation of China(22177041,22277042,22077052,22107037,22207042) the China Postdoctoral Science Foundation(2021M691279) the 111 Project(111-2-06) the Max Planck Society International Partner Group Program,and the China Scholarship Council(CSC)for funding.P.H.S.thanks the Max Plank Society forgenerous financial support
主 题:Glycoconjugates Helicobacter pylori Immunology Microarrays O-antigen Oligosaccharides
摘 要:Helicobacter pylori(***)infection is a threat to human *** lipopolysaccharide(LPS)O-antigen holds promise for developing *** is meaningful to explore the immunological activity of oligosaccharides with different lengths and frameshifts for antigen ***,a glycan library of *** O2 O-antigen containing eight fragments is *** screening with *** O2 LPS sera and patients’sera by glycan microarray,the disaccharide HPO2G-2b and trisaccharide HPO2G-3a show strong antigenicity and then are separately conjugated with carrier protein *** glycoconjugates elicit a robust immunoglobulin G(IgG)immune response in *** anti-HPO2G-3a IgG antibodies possess a much stronger binding affinity with the LPS and bacteria of *** O2 than the anti-HPO2G-2b IgG *** is no cross-reaction between both sera IgG antibodies with LPS and bacteria of *** O1,O6,and *** results demonstrate the trisaccharide HPO2G-3a is a promising candidate for *** vaccine development.